Matrix Metalloproteinase-9 (MMP9) Antibody

Documentos del producto

Especificaciones del producto

Primary Antibodies

Target: Matrix Metalloproteinase-9 (MMP9)

Mouse

Rabbit

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

Unconjugated

Purified by Protein A and Protein G affinity chromatography.

1 ml

Liquid

WB, IHC, IF/ICC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Please enquire.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

P41246

GELB,CLG4B,MMP-9,MANDP2,92 kDa type IV collagenase, Gelatinase B

Antibody anti-MMP9

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Background

Matrix metalloproteinase 9 (MMP9), also known as gelatinase B, is an enzyme belonging to the matrix metalloproteinase family. MMP-9 is a zinc-dependent endopeptidase. It is synthesized as a proenzyme, and requires activation by other proteases to become active. The active form of MMP-9 can degrade various components of the extracellular matrix, including collagen type IV, which is a major component of the basement membrane. MMP-9 is implicated in several physiological and pathological processes, including tissue remodeling, angiogenesis, wound healing, inflammation, and cancer metastasis. It is involved in the breakdown of the extracellular matrix, which is essential for processes like tissue repair and remodeling. However, dysregulation of MMP-9 activity can contribute to pathological conditions such as excessive tissue degradation, tumor invasion, and metastasis.MMP-9 activity is tightly regulated at multiple levels, including transcriptional regulation, post-translational modification, and inhibition by tissue inhibitors of metalloproteinases (TIMPs)